Generics Co. Resists Allergan's Bid To Leave Restasis IPRs
Allergan Inc.'s request to leave a series of patent challenges tied to its dry-eye medication Restasis should be rejected because the company's deal to transfer the patents to a Native American...To view the full article, register now.
Already a subscriber? Click here to view full article